DarioHealth (DRIO) Q3 2024 earnings summary

Executive summary

• Achieved 111% year-over-year revenue growth in Q3 2024, reaching $7.42 million, driven by commercial channel growth and Twill acquisition.

• Integrated Twill acquisition, expanding into behavioral health and enhancing platform capabilities for six chronic conditions.

• Transitioned to a SaaS-like, high-margin, recurring revenue model, with B2B2C gross margins at 83% and overall non-GAAP gross margins at 70%.

• Workforce reduced by 27% in 2024 to control operating expenses.

• Company warns of substantial doubt about ability to continue as a going concern due to insufficient cash to fund operations for 12 months.

Financial highlights

• Q3 2024 revenue was $7.42 million, up 18.7% sequentially and 111% year-over-year; nine months: $19.4 million (up 16.1% YoY).

• Q3 2024 net loss: $12.3 million, a 21.6% improvement from Q3 2023; nine-month net loss: $33.1 million, down 26.6% YoY.

• Q3 2024 gross profit: $3.9 million (52.2% margin); nine months: $9.1 million (46.6% margin).

• Non-GAAP operating expenses reduced to $12.3 million, a 15.9% sequential decline from Q2 2024.

• Cash and equivalents at September 30, 2024: $15.5 million, down from $36.8 million at year-end 2023.

Outlook and guidance

• Targeting a $50 million revenue run rate and cash flow break-even by end of 2025.

• Current cash on hand is not sufficient to fund projected operating requirements for one year; additional capital needed.

• Expecting further OpEx reductions, with a new baseline of $41 million annualized non-GAAP OpEx by Q1 2025.

• Anticipate continued growth in B2B2C revenue, with 50%-70% growth expected for 2024.

• Integration of Twill expected to drive synergies and expand multi-condition digital health platform.